AccessMyLibrary provides FREE access to over 30 million articles from top publications available through your library.
Create a link to this page
Copy and paste this link tag into your Web page or blog:
2002 JUN 19 - (NewsRx.com & NewsRx.net) -- by Maria G. Essig, MS, ELS, senior medical writer - Researchers in Tokyo have infected metastatic brain tumors with a replication-conditional type of herpes simplex virus (HSV) and saw stimulation of anti-HSV T cells that induced antitumor effects.
Treatment of brain cancer is complicated by being located in an immunologically privileged location of the central nervous system. M. Toda and colleagues at the Institute for Advanced Medical Research in Tokyo used BALB/c mice, which produce intracranial and subcutaneous mouse CT26 colon adenocarcinoma tumors, for testing a novel approach to brain cancer treatment.
The researchers injected a replication-conditional mutant herpes simplex virus (G207) into the subcutaneous CT26 tumors of the BALB/c mice. Although G207 stimulated a cytotoxic T-cell response to both HSV and a tumor antigen, it had little effect on metastatic brain tumors (Immuno-viral therapy of brain tumors by combination of viral therapy with cancer vaccination using a replication-conditional HSV, Cancer Gene Therapy, 2002;9(4):356-364).
Injecting G207 into the subcutaneous and intracranial CT26 tumors generated a significant antitumor effect on the brain metastases. Performing this same procedure in athymic mice failed to produce the same antitumor effects, indicating the mechanism may involve ...
Source: HighBeam Research, Herpes simplex virus aids treatment for metastatic brain...